Clinical models with serum NGAL and serum FGF23 showed high discrimination and calibration; therefore, our study suggested both serum NGAL and serum FGF23 could optimize the clinical models in early identifying CIN. The gene discussed is FGF23; the disease is cervical squamous intraepithelial neoplasia.